Chesapeake Asset Management’s Novo Nordisk NVO Stock Holding History

Chesapeake Asset Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.68K	Buy	+35	New	+$1.5K	﹤0.01%	342
2025 Q2	–	Sell	-156	Closed	-$10.8K	–	473
2025 Q1	$10.8K	Hold	156	–	–	0.01%	199
2024 Q4	$13.4K	Hold	156	–	–	0.01%	189
2024 Q3	$18.6K	Hold	156	–	–	0.02%	175
2024 Q2	$22.3K	Hold	156	–	–	0.02%	159
2024 Q1	$20K	Hold	156	–	–	0.02%	163
2023 Q4	$16.1K	Hold	156	–	–	0.01%	204
2023 Q3	$14.2K	Buy	+156	New	+$13.7K	0.01%	220

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Chesapeake Asset Management's NVO Position: Q2 2026 in Review

Chesapeake Asset Management opened a new position in Novo Nordisk (NVO) in Q2 2026: 35 shares worth $1.68K. The stake represents ﹤0.01% of the portfolio and ranks #342 among its holdings. This is a return to the name: Chesapeake Asset Management previously reported a position in NVO as recently as Q1 2025.

Chesapeake Asset Management first reported a position in NVO in Q3 2023 and has held it in 8 quarters since. The position peaked at $22.3K in Q2 2024. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Chesapeake Asset Management held 35 shares of Novo Nordisk worth $1.68K as of Q2 2026.
Novo Nordisk was a new Chesapeake Asset Management position in Q2 2026.
Novo Nordisk made up ﹤0.01% of Chesapeake Asset Management's portfolio in Q2 2026, its #342 holding.
Chesapeake Asset Management first reported a position in Novo Nordisk in Q3 2023 and has held it in 8 quarters since.
Chesapeake Asset Management's Novo Nordisk position peaked at $22.3K in Q2 2024.
1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Chesapeake Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.